This Week in PLOS

In PLOS Genetics, researchers from Finland and Sweden describe recurrent mutations that they detected in uterine leiomyosarcoma tumors using exome sequencing. In comparing protein-coding sequences in 19 uterine leiomyosarcoma tumors with matched normal samples, the team uncovered 43 genes that were mutated more than once. The top culprits were the TP53, ATRX, and MED12 genes, which were mutated in 33 percent, 26 percent, and 21 percent of the tumors, respectively.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.